Staff Investigators

职员调查员

基本信息

批准号：
7529414
负责人：
FRANK M. TORTI
金额：
$ 4.58万
依托单位：
WAKE FOREST UNIVERSITY HEALTH SCIENCES
依托单位国家：
美国
项目类别：
财政年份：
2007
资助国家：
美国
起止时间：
2007-07-11 至 2012-01-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/7529414
关键词：
American Society of Clinical Oncology Angiogenesis Inhibitors Antineoplastic Agents Archives Area Award B-Lymphocytes Biological Markers Biopsy Breast Cancer Center Cells Chairperson Cisplatin Clinic Clinical Clinical Investigator Clinical Research Clinical Trials Clinical Trials Design Combination Chemotherapy Comprehensive Cancer Center Conduct Clinical Trials Correlative Study Data Development Developmental Therapeutics Program Diagnosis Diffuse Disease Disease-Free Survival Drug Kinetics Eastern Cooperative Oncology Group End Point Ensure Epidermal Growth Factor Receptor Etoposide Extensive Stage FCGR3B gene Faculty Follicular Lymphoma Funding Genes Genetic Polymorphism Group Meetings Guidelines Hematologic Neoplasms Hematology Hodgkin Disease Immune response Immunohistochemistry Institution International Ireland Joints K-Series Research Career Programs Laboratories Leadership Limited Stage Lung Lymphoma MS4A1 gene Malignant Neoplasms Malignant neoplasm of lung Manuals Medicine Medlone 21 Mentored Clinical Oncology Award Mentored Clinical Scientist Award Mentored Patient-Oriented Research Career Development Award Methods Molecular Molecular Profiling Monoclonal Antibodies Monoclonal Antibody Therapy Multidrug Resistance Gene Non-Hodgkin&apos s Lymphoma Operative Surgical Procedures Oral Outcome Participant Pathway interactions Patients Peripheral Pharmaceutical Preparations Pharmacology Shared Resource Phase Phase I Clinical Trials Phase I/II Trial Phase II Clinical Trials Population Predictive Factor Predictive Value Principal Investigator Prior Therapy Prognostic Factor Protein Tyrosine Kinase Radiation Radioimmunotherapy Refractory Relapse Research Research Activity Research Design Research Personnel Research Project Grants Resource Sharing Retrospective Studies Role STAT3 gene Science Site Southwest Oncology Group Staging Stem cell transplant Stem cells T-Cell Lymphoma T-Lymphocyte Testing Therapeutic Time Tissue Microarray Tissues Translating Translational Research Translational Research Shared Resource University Hospitals Vascular Endothelial Growth Factors Work authority base bevacizumab cancer pharmacology cancer research center director chemotherapy clinical effect concept design drug development experience gemcitabine improved inhibitor/antagonist lapatinib lung small cell carcinoma lymph nodes macrophage member model development novel novel therapeutics oncology professor programs protocol development quality assurance response rituximab tositumomab translational study tumorigenesis

项目摘要

Two staff investigators are proposed, both to serve in the function as Deputy Associate Directors for Clinical Research. Dr. Afshin Dowlati, an expert in novel therapeutic development in lung cancer, and Dr. John Sweetenham, an expert in lymphoma therapeutics, are both accomplished clinical investigators with considerable leadership capacity to coordinate clinical trials research emphasizing investigator-initiated efforts. As staff investigators, they will have focused time to devote to clinical trials development and oversight with special emphasis on investigator-initiated trials that cut across scientific programs and involve the Case CCC clinical trials disease teams. As staff investigators, they will have the prominence and authority to assist investigators in protocol development and design, and in efficient, safe management with a high degree of quality assurance during early phase drug development.

Two staff investigators are proposed, both to serve in the function as Deputy Associate Directors for Clinical 研究。 Dr. Afshin Dowlati, an expert in novel therapeutic development in lung cancer, and Dr. John Sweetenham, an expert in lymphoma therapeutics, are both accomplished clinical investigators with considerable leadership capacity to coordinate clinical trials research emphasizing investigator-initiated 努力。 As staff investigators, they will have focused time to devote to clinical trials development and oversight with special emphasis on investigator-initiated trials that cut across scientific programs and involve the Case CCC clinical trials disease teams. As staff investigators, they will have the prominence and authority to assist investigators in protocol development and design, and in efficient, safe management with a high degree of quality assurance during early phase drug development.